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Abstract: We assessed the association between the use of lower- and higher-than-recommended
doses of folic acid supplements (FAs) during pregnancy and attentional function in boys and girls at
age of 4–5. We analyzed data from 1329 mother-child pairs from the mother-child cohort INfancia
y Medio Ambiente Project (INMA) study. Information on FAs use during pregnancy was collected
in personal interviews at weeks 12 and 30, and categorized in <400, 400–999 (recommended dose),
and ≥1000 µg/day. Child attentional function was assessed by Conners’ Kiddie Continuous Per-
formance Test. Multivariable regression analyses were used to estimate incidence rate ratios (IRR)
and beta coefficients with 95% confidence intervals (CI). Compared to recommended FAs doses,
the periconceptional use of <400 and ≥1000 µg/day was associated with higher risk of omission
errors—IRR = 1.14 (95% CI: 1.01; 1.29) and IRR = 1.16 (95% CI: 1.02; 1.33), respectively. The use of FAs
< 400 µg/day and ≥1000 µg/day was significantly associated with deficits of attentional function
only in boys. FAs use < 400 µg/day was associated with higher omission errors with IRR = 1.22
and increased hit reaction time (HRT) β = 34.36, and FAs use ≥ 1000 µg/day was associated with
Nutrients 2021, 13, 327. https://doi.org/10.3390/nu13020327 https://www.mdpi.com/journal/nutrients
Nutrients 2021, 13, 327 2 of 16
increased HRT β = 33.18 and HRT standard error β = 3.31. The periconceptional use of FAs below or
above the recommended doses is associated with deficits of attentional function in children at age of
4–5, particularly in boys.
Keywords: folic acid; supplement use; pregnancy; attentional function; neurodevelopment; children
1. Introduction
An adequate dietary intake and periconceptional use of folic acid supplements during
the embryonic period is crucial in several fetal physiological and cellular processes [1]
that are essential for the optimal early and late development of the child’s brain and
cognitive function [2,3]. The folic acid (synthetic form of folate) is an essential micronutrient
required for many metabolic processes such as the metabolism of carbon-1 and for S-
adenosylmethionine (SAM) production [4], nucleotide synthesis, DNA repair, methylation
reactions, myelination, and synthesis of neurotransmitters [5,6]. There is also evidence from
animal studies suggesting that the effect of folic acid supplements (FAs) modulating DNA
methylation reactions and the brain development of the child, may be different according
to sex [7].
Based on the initial results of the Medical Research Council (MRC) clinical trial and
subsequent evidence, a daily dose of 400 µg/day from folic acid (FA) in the periconceptional
period is recommended to reduce the risk of neural tube defects [8,9]. Thus, in many
countries, women planning to become pregnant are advised to take this dosage of FAs, to
avoid exceeding the tolerable upper limit of 1000 µg/day, and to eat varied diets rich in
dietary folate. In Spain, there is no information on FA status at national level, although in a
population-based mother-child cohort study in Valencia, the periconceptional mean daily
FA intake was 304 µg, lower than the recommended dietary intake [10]. The proportion of
women using FA supplements in preconception, the first month, and the second month of
pregnancy was 19%, 30%, and 66% respectively; and among women using FA supplements
in the periconceptional period, 30% exceeded the upper tolerable limit (UTL) for FAs of
1.000 µg/day [10].
Recently published studies suggest that the use of FAs during pregnancy at doses
below or above the present recommendations during the periconceptional period of preg-
nancy may cause changes in the fetal brain, which can alter the future child’s cognitive and
motor processes [11,12]. In fact, a deficient FAs use in pregnancy has been associated with
poorer cognitive skills in children [13], and in our study over a half of pregnant women
used low doses of FAs (<400 µg/day, including no use) [14]. Moreover, one-third of the
pregnant women in our study used high FAs doses above 1000 µg/day (3.5% consuming
>5000 µg/day), which has been also related to psychomotor delay at one year of age [15],
and cognitive deficits at 4–5 years of age [16], especially in verbal function. In this sense,
early childhood and preschool age are appropriate periods to investigate the potential
cognitive effects of the use of FAs, since the prefrontal cortex, the brain area related to
superior cognitive functions, achieves its synaptic formation peak at the age of 4 years,
approximately [17,18].
The negative effects of low or high of FAs doses on cognitive function have been also
shown in an animal studies with mice models. In one study, three type of diets were used:
one group containing no FA (low doses), another group with high doses of FA (20 mg/kg),
and a control group with the recommended doses (2 mg/kg). Compared to offspring
from the control group, those from the low and high doses groups presented structural
and physiological neurodevelopmental abnormalities such as thinner cortex, persistent
deviation in cortical cytoarchitectural organization, less complex dendritic arbors (which
could be related to neuronal dysfunction [19], delay in prenatal neurogenesis, and an
increased apoptosis in the developing cortex. In addition, compared to mice exposed to
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recommended doses, the FA-deficient offspring underperformed in memory tests and the
exposed to high FA doses showed an increased open space-induced anxiety [20].
Nevertheless, little is still known regarding the effect of high or low FAs doses in
children’s attentional function. Attentional function is crucial to children’s social relations
and learning [21]. It is a superior cognitive function, which involves different processes,
such as focus on a specific stimulus during a period of time to process it adequately,
while ignoring other stimuli from the environment [22]. Their development begins in the
embryonic period, in which the brain is very vulnerable to environmental factors such as
the mother’s diet [23,24], and it continues until adolescence [25,26]. A recently published
review [27] describes the importance of the maternal use of FAs at recommended doses in
order to reduce inattention symptoms in school-age children and improve attention and
concentration in adolescents. Thus, our hypothesis is that the use of lower (<400 µg/day)
or higher (≥1000 µg/day) doses of FAs during pregnancy compared to the recommended
use (400–999 µg/day) may produce attentional dysfunction in children at 4–5 years of age.
Therefore, we aim to evaluate the association between the use of FAs at doses below or
above the recommended in pregnancy and attentional function in children at 4–5 years
of age.
2. Materials and Methods
2.1. Study Design and Population
The INMA—INfancia y Medio Ambiente [Environment and Childhood] Project—is
a population-based prospective birth cohort study, established in seven regions of Spain
following a common protocol [28]. In the current study, we used the data collected from the
INMA regions of Valencia, Sabadell (Catalonia), Asturias, and Gipuzkoa (Basque-country).
These four cohorts were established between 2003 and 2008. Detailed information on the
population and study design has been published elsewhere [28]. Briefly, participants were
recruited during the first prenatal visit, between weeks 10 and 13 of gestation at public
primary health care centers or public hospitals. Women who agreed to participate were
followed up at the third trimester of gestation; delivery; when children were 1 year of age;
and at 4–5 years of age. Of the available 2764 women, 139 women were excluded from
the study due to withdrawal, being unavailable for follow-up, induced or spontaneous
abortions, or fetal deaths. A total of 2625 women delivered a live infant between May
2004 and August 2008, and 2049 children participated at the 4-year follow-up assessment.
Finally, for the present study, 1329 mother-child pairs were included with available data
on the main variables when children were aged 4 to 5. Figure 1 shows the flowchart
of the population sample in our study. The final analysis was based on 1329 children
since the attentional function assessment was introduced late in the 4–5 years follow-
up. All participants gave informed written consent in each phase of the study prior to
participation, and the Institutional Ethical Committees of the participating centres involved
in the study approved the research protocol (CEIC-Hospital La Fe, Valencia; CEIC-Hospital
de Zumárraga, Gipuzkoa; CEIC-Parc de Salut Mar, Barcelona; CEIC-Hospital Universitario
Central de Asturias).
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2.2. Dietary Folate and FAs Intake during Pregna cy
The asse sment of dietary folate and FAs intake has been described previously [15,29]
(av il ble at: http://epinut.edu. mh.es/cfa-101-inma-embarazadas/). Briefly, validated
food frequency questionnaires (FFQs) [30] were administered to pregnant women at 10–13
and 28–32 weeks to estimate dietary nt kes from th ee months preconcepti to the third
month of pregnancy, a d from the ourth to the seventh month of pregnancy, respectively.
The folate content of food was primarily obtained from USDA food composition tables [31]
and other Spanish-published sources [32]. In the pres nt study, w estimated the typical
diet ry folate intake for the perico ceptional period, for the second–third t im st r of
pregnancy, and for the average of these two periods combin d (entire pregnancy).
The consumption of FAs or vitamin and mineral preparations containing FAs were
obtained thr ugh s ecific supplement questions of the FFQ. FAs use was estimated based
on daily dose, s pplement brand na e and composition, and duration of consu ption for
each period of pregnancy. We estimated the monthly use of FAs and the average for each
woman in periconceptional period, the second period of pregnancy, and during the entire
pregnancy. After that, we categorized the use of FAs in these periods as <400 µg/day, 400–
999 µg/day (this was used as the reference category in the analyses), and ≥1000 µg/day,
similarly as we have done in previous work [16].
2.3. Children’s Attentional Function Assessment
Attentional function was measured at the median age of 4.6 years using Conner’s
Kiddie Continuous Performance Test (K-CPT) [33] although in Valencia, the median age
of children was 5.8 years. The K-CPT (K-CPT TM v.5) is a 7.5-min computerized test
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that examines inattention, impulsivity, sustained attention, and vigilance in children aged
4 to 7 years [34]. This test was administered to children individually in a quiet room
by trained fieldworkers. Children were instructed to press the space bar on the key-
board as fast as possible when they saw an image on the computer screen (the target),
unless that image was a ball (the non-target). The main five interest measures of the
K-CPT included (Table S1): omission errors (i.e., the number of times the child did not
respond to a target); commission errors (i.e., the number of times the child responded
erroneously to a non-target); hit reaction time (HRT, the mean response time—expressed
in milliseconds—for all correct responses during the entire test); standard error of the hit
reaction time [HRT(SE); the within-child variability of the HRTs, which is a measure of
speed response consistency—expressed in milliseconds—throughout the test [35], and
finally, the detectability of attentiveness (d’, a measure—without units—which shows the
children’s capacity to distinguish a target from a non-target stimulus [33,36]). Higher scores
in the K-CPT outcomes mean adverse attention results, with the exception of detectability.
2.4. Other Variables
Information on potential confounders were obtained from questionnaires completed
at the personal interview in pregnancy. These questionnaires included information on
sociodemographic and lifestyle factors such as: mother’s characteristics (location (Asturias;
Gipuzkoa; Sabadell; Valencia), age (in years), energy intake (in kilocalories), social class (I
+ II [high], III [medium], or IV + V [low]), educational level (primary or less, secondary,
or university), parity (0 or ≥1), overall tobacco exposition (yes/no), BMI pre-pregnancy
(continuous)); father’s BMI (continuous); and child’s characteristics (sex (male, female) and
age at K-CPT examination (in years)).
2.5. Statistical Analysis
Descriptive analysis of sociodemographic, lifestyle, and obstetric characteristics of
pregnant women was performed for the four areas of the INMA project. To explore the
normal distribution of the quantitative variables, we used the Kolmogorov test. More-
over, we used the Chi-square test for qualitative variables and the Kruskal-Wallis test for
quantitative variables.
All the covariates with p value >0.20 in bivariate analysis and those that changed
the magnitude of the main effects by >10% after a backward elimination procedure were
included in the core model. Multiple robust linear regression models using an MM-type
estimator was performed to evaluate the association between FAs use and K-CPT outcomes
(HRT, HRT (SE), and detectability) for each pregnancy period: the periconceptional period,
second period of pregnancy, and throughout the entire pregnancy [37]. Multiple negative
binomial regression models were used to estimate associations between FAs use and K-CPT
count outcomes (number of omission errors and number of commission errors) for each
period of pregnancy [38]. The regressions coefficients of negative binomial models were
exponentiation to obtain IRR (incidence rate ratios) which should be interpreted as relative
risk. Besides this, to obtain combined estimates for the four study cohorts, we used a
meta-analysis. Heterogeneity was quantified with the I2 statistic under the fixed-effects
hypothesis (I2 ≤ 50%), and when heterogeneity was detected (I2 > 50%), the random effects
model was used [39]. To verify potential effect modification, additional models stratified
by sex of the children were run.
Sensitivity analysis was performed to analyze the robustness of the main findings.
We added mother or child conditions that could be related to child cognitive function
development as a different adjustment to the basal model. So, we included in the basal
model maternal variables such as iodine intake from supplements; fish consumption during
pregnancy; verbal reasoning outcome of the similarities subtest of the Wechsler Adult Intel-
ligence Scale-III; time of initiating FAs usage; NO2 exposition during pregnancy; and use of
acetaminophen during pregnancy. In addition, we ran the basal model with child variables
such as dietary folate intake assessed by validated FFQ. Finally, to avoid any potential
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influence in the association, we conducted the basal model after excluding subjects with
some conditions such as preterm deliveries (n = 1273), mothers with medical conditions
that could affect the typical development of cognitive functions (diabetes mellitus, epilepsy,
or thyroid disease) (n = 1079), mothers who did not use FAs throughout their entire preg-
nancies (n = 1258), children who met the WHO obesity criteria (97th percentile) (n = 1192),
children with psychomotor delay on the Bayley Scales of Infant and Toddler development
(BSID) at age 1 year (<85th percentile) (n = 1207), and children with low scores in executive
function on the McCarthy Scales of Children’s Abilities (MSCA) (<76.3 score) (n = 1248).
We also performed sensitivity analyses stratifying by boys and girls.
Statistical analyses were conducted with R 3.4.2 (R Foundation for Statistical Computing).
3. Results
The baseline characteristics of the pregnant women and their children according to
the four areas of the study are shown in Table 1. Overall, the median age of the mothers
was 31 years, more than a third (36.3%) had completed university studies, and almost half
of them (48.8%) had low social class.










(n = 264) p
1
Mother’s age, year 31 (28–34) 30 (28–33) 31 (28–34) 31 (29–35) 31 (29–33) <0.001
Educational level
Primary or less 285 (21.4) 144 (27.8) 73 (24.3) 40 (16.3) 28 (10.6) <0.001
Secondary 561 (42.2) 226 (43.6) 121 (40.2) 111 (45.1) 103 (39.0)
University 483 (36.3) 148 (28.6) 107 (35.5) 95 (38.6) 133 (50.4)
Social class
I + II (high) 312 (23.5) 99 (19.1) 70 (23.3) 60 (24.4) 83 (31.4) <0.001
III 368 (27.7) 138 (26.6) 100 (33.2) 56 (22.8) 74 (28.0)
IV + V (low) 649 (48.8) 281 (54.2) 131 (43.5) 130 (52.8) 107 (40.5)
Parity ≥ 1 564 (42.4) 234 (45.2) 129 (42.9) 92 (37.4) 109 (41.3) 0.230
Overall tobacco exposition
during pregnancy, yes 810 (61.0) 370 (71.4) 179 (59.5) 108 (43.9) 153 (58.0) <0.001
Missing values 26 (1.3) 6 (1.2) 6 (2.0) 12 (4.9) 2 (0.8)
Prepregnancy mother’s BMI,
kg/m2
<18.5–25 982 (73.9) 368 (71.0) 232 (77.1) 172 (69.9) 210 (79.5) 0.045
>25–30 251 (18.9) 103 (19.9) 50 (16.6) 58 (23.6) 40 (15.2)
>30 96 (7.2) 47 (9.1) 19 (6.3) 16 (6.5) 14 (5.3)
Prepregnancy father’s BMI,
kg/m2
<18.5–25 569 (42.8) 226 (43.6) 142 (47.2) 75 (30.5) 126 (47.7) <0.001
>25–30 574 (43.2) 233 (45.0) 112 (37.2) 120 (48.8) 109 (41.3)
>30 164 (12.5) 59 (11.4) 43 (14.3) 42 (17.1) 20 (7.6)
Missing values 22 (1.7) 0 (0.0) 4 (1.3) 9 (3.7) 9 (3.4)
Child’s sex, male 664 (50.0) 267 (51.5) 153 (50.8) 121 (49.2) 123 (46.6) 0.600
Child’s sex, female 665 (50.0) 251 (48.5) 148 (49.2) 125 (50.8) 141 (53.4)
Age at K-CPT examination, year 4.6 (4.4–5.7) 5.8 (5.7–5.8) 4.5 (4.4–4.6) 4.4 (4.3–4.5) 4.5 (4.4–4.5) <0.001
Dietary folate, µg/day
First period 294 (237–359) 294 (234–360) 282 (231–343) 312 (245–370) 307 (246–365) 0.003
Second period 291 (235–358) 278 (220–353) 289 (233–348) 300 (242–365) 302 (259–369) <0.001
FAs µg/day
First period
<400 742 (55.8) 309 (59.7) 190 (63.1) 112 (45.5) 131 (49.6) <0.001
400–999 199 (15.0) 80 (15.4) 35 (11.6) 42 (17.1) 42 (15.9)
≥1000 388 (29.2) 129 (24.9) 76 (25.2) 92 (37.4) 91 (34.5)











(n = 264) p
1
Second period
<400 683 (51.4) 169 (32.6) 252 (83.7) 66 (26.8) 196 (74.2) <0.001
400–999 405 (30.5) 246 (47.5) 35 (11.6) 88 (35.8) 36 (13.6)
≥1000 241 (18.1) 103 (19.9) 14 (4.7) 92 (37.4) 32 (12.1)
K-CPT outcomes
HRT, ms 705 (633–792) 669 (604–735) 718 (647–803) 758 (678–843) 733 (659–845) <0.001







Detectability, no unit 0.6 (0.3–0.9) 0.5 (0.3–0.8) 0.5 (0.3–0.8) 0.7 (0.3–1.0) 0.6 (0.3–0.9) 0.011
Omissions, number 18 (9–34) 10 (5–20.75) 24 (13–37) 23 (13–37.75) 31 (16.75–50) <0.001
Commissions, number 21 (13–29) 22 (15–29) 22 (15–31) 16.5(10–30.75) 18 (11–28) <0.001
First period, periconceptional period of pregnancy; second period, from the fourth to the seventh month of pregnancy; FAs, folic acid
supplement; HRT, hit reaction time (ms); HRT(SE), hit reaction time standard error (ms); INMA, Infancia y Medio Ambiente; K-CPT,
Conners’ Kiddie Continuous Performance Test; ms, milliseconds; num, number. Values are medians (IQRs) for mother’s age, age at K-CPT
examination, dietary folate, and K-CPT outcomes; and values are n (%) for the rest of variables. 1 p values of differences between study
cohorts from the Chi-square test (categorical variables) and Kruskal-Wallis test (continuous nonparametric variables).
A total of 55.8% of the mothers used <400 µg/day FAs doses and 29.2% used
≥1000 µg/day FAs doses in the periconceptional period. In this period, the highest
proportion of pregnant women taking <400 µg/day FAs doses were from Sabadell (63.1%),
while the highest proportion of pregnant women taking ≥1000 µg/day FAs doses were
from Asturias (37.4%) (χ2 = 26.986, 6 d.f., p = 0.00014). In the second period of pregnancy,
51.4 and 18.1% of the mothers used doses of <400 µg/day and ≥1000 µg/day FAs, re-
spectively. In this period, an important proportion of mothers from Valencia (19.9%) and
Asturias (37.4%) continued taking ≥1000 µg/day FAs doses (χ2 = 350.2, 6 d.f., p < 0.0000002)
(Table 1). Children from Valencia showed lower results in most KCP-T outcomes compared
to children from other study areas, although they showed the highest scores in the number
of commission errors together with children from the Sabadell area (Kruskal-Wallis χ2 =
24.823, 3 d.f., p = 0.000016) (Table 1).
Table 2 presents the fully-adjusted models with the combined associations between
use of FAs and K-CPT outcomes in the different periods of pregnancy. Compared to the
periconceptional use of recommended FAs doses (400–999 µg/day), the periconceptional
FAs use of <400 µg/day and ≥1000 µg/day was associated with a 14% (IRR = 1.14; 95%
CI = 1.01 to 1.29) and 16% (IRR = 1.16; 95% CI = 1.02 to 1.33) of increase in the number of
children’s omission errors, respectively. The associations between the periconceptional use
of non-recommended FAs doses and the number of omission errors in each area of study
were similar to the combined results, but in the Valencia area the number of associations
was slightly higher and reached statistical significance (Figure 2). There were no statistically
significant associations in other K-CPT outcomes or in other periods of pregnancy. We
explored the interactions between overall tobacco exposition and the use of FAs during the
periconceptional period but none were significant.
When the analysis was stratified by sex, the positive association found between
periconceptional FAs use of <400 µg/d and the increased number of omission errors was
only observed in boys (IRR = 1.22; 95% CI = 1.01 to 1.47), this FAs use was also associated
with a higher HRT in boys (β = 34.36; 95% CI = 10.01 to 58.71) (Figure 2). In addition, the
periconceptional FAs use of ≥1000 µg/day was associated with a higher HRT in boys (β =
33.18; 95% CI = 6.10 to 60.25) and a higher HRT (SE) (β = 3.31; 95% CI = 0.53 to 6.09). In girls,
we only observed a protective association between the FAs use of <400 µg/day during the
second period of pregnancy and decreased number of omission errors (IRR = 0.86; 95%
CI = 0.74 to 1.00) (Table 3). The combined associations between non-recommended FAs
doses and boys’ and girls’ attentional function outcomes were similar to those observed
by cohort. Omission errors and HRT(SE) associations found in boys were slightly higher
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and reached statistical significance only in the Valencia area, whereas the HRT association
found in boys reached statistical significance only in the Gipuzkoa area (Figure 3).
Table 2. Fully-adjusted combined association between folic acid supplement (FAs) use during pregnancy and attentional
function outcomes in children aged 4–5 years of the Infancia y Medio Ambiente (INMA) cohort study, Spain, 2003–2008
(n = 1329).
HRT HRT(SE) Detectability Omissions Commissions
β 1 (95% CI) p I2 β 1 (95% CI) p I2 β 1 (95% CI) p I2 IRR 1 (95% CI) p I2 IRR 1 (95% CI) p I2
First period
FAs, µg/day
400–999 Ref. Ref. Ref. Ref. Ref.
<400 14.56 (−3.26; 32.38) 0.109 0.0 1.01 (−0.69; 2.70) 0.244 0.0 0.03 (−0.11; 0.16) 0.685 75.5 1.14 (1.01; 1.29) 0.035 0.0 0.96 (0.83; 1.12) 0.633 66.1
≥1000 9.06 (−11.02; 29.14) 0.376 0.0 1.73 (−0.13; 3.60) 0.068 0.0 −0.00 (−0.16; 0.15) 0.986 79.0 1.16 (1.02; 1.33) 0.027 0.0 0.99 (0.83; 1.19) 0.941 72.3
Second period
FAs, µg/day
400–999 Ref. Ref. Ref. Ref. Ref.
<400 3.80 (−11.23; 18.83) 0.620 0.0 −1.25 (−2.70; 0.21) 0.094 9.3 0.02 (−0.04; 0.08) 0.455 0.0 0.91 (0.82; 1.02) 0.097 0.0 0.97 (0.91; 1.04) 0.426 0.0
≥1000 −1.39 (−21.45; 18.67) 0.892 0.0 0.41 (−3.25; 4.07) 0.825 52.7 −0.02 (−0.09; 0.05) 0.568 0.0 1.02 (0.90; 1.16) 0.773 6.3 1.03 (0.95; 1.12) 0.442 0.0
Entire pregnancy
FAs, µg/day
400–999 Ref. Ref. Ref. Ref. Ref.
<400 −9.52 (−38.06; 19.02) 0.513 52.4 −0.41 (−1.98; 1.16) 0.607 22.0 −0.03 (−0.20; 0.15) 0.775 86.9 0.95 (0.77; 1.17) 0.624 70.0 1.05 (0.85; 1.29) 0.666 83.9
≥1000 −10.94 (−30.28; 8.41) 0.268 1.0 −0.07 (−1.83; 1.69) 0.934 41.1 −0.01 (−0.17; 0.14) 0.894 76.9 0.98 (0.80; 1.19) 0.838 56.8 1.02 (0.83; 1.26) 0.826 79.1
First period, periconceptional period of pregnancy; second period, from the fourth to the seventh month of pregnancy; FAs, folic acid
supplements; INMA, Infancia y Medio Ambiente; HRT, hit reaction time (ms); HRT(SE), hit reaction time standard error (ms); omissions,
omission errors (n); commission, commission errors (n); β, beta coefficient from multiple robust linear regression; 95% CI, 95% confidence
interval; I2, index to quantify the degree of heterogeneity in a meta-analysis; IRR, incidence rate ratio from negative binomial regression.
1 Cohort-specific models were combined using meta-analysis. All models were adjusted by energy intake (in kilocalories), dietary
folate intake per 100 µg/day increase, social class (I + II (high), III or IV + V (low)), educational level (primary or less, secondary or
university), parity (0 or ≥1), overall tobacco exposition during the periconceptional period (no or yes), mother’s age (in years), mother’s
BMI (continuous), father’s BMI (continuous), child’s sex and child’s age at K-CPT examination (in years). We used the results from the
fixed-effects meta-analysis model when I2 was less than 50% and from the random-effects meta-analysis model when I2 was greater
than 50%.
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When the analysis was stratified by sex, the positive association found between 
periconceptional FAs use of <400 μg/d and the increased number of omission errors was 
only observed in boys (IRR = 1.22; 95% CI = 1.01 to 1.47), this FAs use was also associated 
with a higher HRT in boys (β = 34.36; 95% CI = 10.01 to 58.71) (Figure 2). In addition, the 
periconceptional FAs use of ≥1000 μg/day was associated with a higher HRT in boys (β = 
33.18; 95% CI = 6.10 to 60.25) and a higher HRT (SE) (β = 3.31; 95% CI = 0.53 to 6.09). In 
girls, we only observed a protective association between the FAs use of <400 μg/day dur-
ing the second period of pregnancy and decreased number of omission errors (IRR = 0.86; 
95% CI = 0.74 to 1.00) (Table 3). The combined associations between non-recommended 
FAs doses and boys’ and girls’ attentional function outcomes were similar to those ob-
served by cohort. Omission errors and HRT(SE) associations found in boys were slightly 
higher and reached statistical significance only in the Valencia area, whereas the HRT as-
sociation found in boys reached statistical significance only in the Gipuzkoa area (Figure 
3). 
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Figure 2. Pooled estimates of the associations between FAs (<400 and ≥1000 µg/day compared to 400–999 µg/day) and
number of omission errors during periconceptional period of pregnancy in all children, boys, and girls at 4–5 years of age.
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Table 3. Fully-adjusted combined association between FAs use during pregnancy and attentional function outcomes in
children aged 4–5 years of the INMA cohort study according to sex; Spain, 2003–2008 (n boys = 664; n girls = 665).
HRT HRT(SE) Detectability Omissions Commissions




400–999 Ref. Ref. Ref. Ref. Ref.




0.14) 0.202 16.5 1.22 (1.01; 1.47) 0.036 8.6 0.92 (0.83; 1.03) 0.153 0.0
≥1000 33.18 (6.10;60.25) 0.016 0.0 3.31 (0.53; 6.09) 0.019 3.7
0.04 (−0.05;
0.13) 0.395 44.8 1.25 (0.91; 1.72) 0.169 60.9 0.97 (0.80; 1.18) 0.752 57.4
Second period
FAs, µg/day
400–999 Ref. Ref. Ref. Ref. Ref.




0.22) 0.490 65.3 0.92 (0.78; 1.09) 0.346 0.0 1.00 (0.91; 1.09) 0.919 37.1




0.02) 0.121 9.2 0.96 (0.80; 1.16) 0.687 0.0 1.10 (0.99; 1.23) 0.072 49.4
Entire pregnancy
FAs, µg/day
400–999 Ref. Ref. Ref. Ref. Ref.




0.09) 0.450 61.4 0.95 (0.70; 1.27) 0.713 71.7 1.07 (0.92; 1.25) 0.405 58.2








400–999 Ref. Ref. Ref. Ref. Ref.




0.26) 0.688 77.8 1.11 (0.94; 1.30) 0.227 0.0 0.98 (0.75; 1.27) 0.855 76.0




0.15) 0.998 50.3 1.10 (0.92; 1.31) 0.302 0.0 0.99 (0.87; 1.13) 0.847 39.6
Second period
FAs, µg/day
400–999 Ref. Ref. Ref. Ref. Ref.




0.12) 0.357 0.0 0.86 (0.74; 1.00) 0.045 0.9 0.95 (0.86; 1.06) 0.358 5.3




0.13) 0.534 0.0 1.02 (0.86; 1.22) 0.792 0.0 0.97 (0.86; 1.11) 0.669 0.0
Entire pregnancy
FAs, µg/day
400–999 Ref. Ref. Ref. Ref. Ref.




0.25) 0.774 80.0 1.00 (0.85; 1.18) 0.976 0.0 1.03 (0.87; 1.10) 0.837 79.5




0.20) 0.710 52.6 0.97 (0.81; 1.17) 0.772 0.0 1.00 (0.80; 1.27) 0.937 53.8
First period, periconceptional period of pregnancy; second period, from the fourth to the seventh month of pregnancy; FAs, folic acid
supplements; INMA, Infancia y Medio Ambiente; HRT, hit reaction time (ms); HRT(SE), hit reaction time standard error (ms); omissions,
omission errors (n); commission, commission errors (n); β, beta coefficient from multiple robust linear regression; 95% CI, 95% confidence
interval; I2, index to quantify the degree of heterogeneity in a meta-analysis; IRR, incidence-rate ratio from negative binomial regression.
1 Cohort-specific models were combined using meta-analysis. All models were adjusted by energy intake (in kilocalories), dietary
folate intake per 100 µg/day increase, social class (I + II (high), III or IV + V (low)), educational level (primary or less, secondary or
university), parity (0 or ≥1), overall tobacco exposition during the periconceptional period (no or yes), mother’s age (in years), mother’s
BMI (continuous), father’s BMI (continuous), and child’s age at K-CPT examination (in years). We used the results from the fixed-effects
meta-analysis model when I2 was less than 50% and from the random-effects meta-analysis model when I2 was greater than 50%.
Sensitivity analyses were conducted to assess the robustness of the association between
the periconceptional use of non-recommended FAs doses and the number of omission
errors under a variety of scenarios in all children and by sex (Figure 4). In all children, the
associations between FAs use of <400 µg/day and the number of omission errors remained
similar to the basal model (IRR = 1.14; 95% CI = 1.01 to 1.29), although we observed a
stronger association when we adjusted for child dietary folate and energy intake (IRR
= 1.17; 95% CI = 1.03 to 1.32) and when we excluded mothers with medical conditions
(IRR = 1.19; 95% CI = 1.04 to 1.37). In addition, the association between the FAs use of
≥1000 µg/day and omission errors in the basal model (IRR = 1.16; 95% CI = 1.02 to 1.33)
became slightly stronger when we excluded those mothers with medical conditions (IRR =
1.20; 95% CI = 1.03 to 1.39). As with the all-children associations, associations between FAs
use of <400 µg/day and the number of omission errors in boys remained very similar to
the basal model (IRR = 1.22; 95% CI = 1.01 to 1.47), although it became stronger when we
adjusted for mother’s acetaminophen use during pregnancy (IRR = 1.24; 95% CI = 1.03 to
1.49) and when we excluded mothers with medical conditions (IRR = 1.26; 95% CI = 1.02
to 1.56). Finally, when we added other variables such as alcohol consumption in grams
day or breastfeeding (no, <20 weeks, or ≥20 weeks) in multivariable models, the observed
associations remained similar and still significant. Similarly, after excluding children with
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missing values or scoring less than 7 in the Apgar test at 1 or 5 min after birth, the results
were unchanged (data not shown).
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μg/day on children’s attentional function at 4–5 years of age, specifically an increased 
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pregnancy is very scarce due to ethical and moral commitments. Therefore, hypotheses 
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4. Discussion
In the present study, we found that, compared to the periconceptional use of the
recommended FAs doses, the use of FAs doses <400 or ≥1000 µg/day was associated with
an increase in the number of omission errors in children at 4–5 years of age. Moreover,
our results suggest that the association may be sex-specific, since only boys presented an
increase in the number of omission errors with mothers taking <400 µg/day of FAs, and an
increase of speed response consistency throughout the test (HRT(SE)) in mothers taking
≥1000 µg/day.
In our study, 266 out of 1329 children scored above the 80th percentile in the number
of omission errors in the K-CPT assessment at the age of 5 years, which may be indicative
of inattention. A prevalence of 18% of inattention in children of 5 years of age was found in
a birth cohort study from United States [40]. In two birth cohorts in China, prevalences of
6.4% [41] and 12.3% [42] were reported for children 3 and 4 years old, respectively, although
they evaluated the prevalence of Attention-Deficit-Hyperactivity Disorders (ADHD) while
we evaluated only attentional function—just one of the ADHD symptoms. In another birth
cohort study from Denmark, a prevalence of 30% was reported for children of 5 years [43].
Thus, it is difficult to make comparisons of inattention prevalence among studies since
specific cut-off points or definitions for inattention are not used consistently yet.
To our knowledge, this is the first prospective study that suggests an increase in
the number of omission errors in children aged 4–5 years with mothers taking non-
recommended FAs doses (<400 or ≥1000 µg/day) compared to mothers taking recom-
mended FAs doses (400–999 µg/day) during the periconceptional period of pregnancy.
On the one hand, we found a negative effect of the periconceptional FAs use of
<400 µg/day on children’s attentional function at 4–5 years of age, specifically an increased
number of omission errors, which is an indicative of inattentiveness [44]. This is a relevant
finding that highlights the need to monitor the compliance of using the recommended
FAs doses among pregnant women to avoid negative effects on the cognitive function of
their children. The evidence evaluating the use of non-recommended FAs doses during
pregnancy is very scarce due to ethical and moral commitments. Therefore, hypotheses like
ours can only be evaluated in prospective birth cohort studies such as the INMA Project.
In one birth cohort study with 420 children in Menorca, Julvez et al. [45] also showed a
significant lower risk of inattention symptom at 4–5 years of age among women using
periconceptional FAs. Similarly, del Río García et al. have shown that maternal dietary
folate deficiency has been related to lower BSID mental scores in 253 Mexican infants [46].
This detrimental effect on attentional function could be related to the maternal folate
deficiency that could affect early brain development [47], and result in a poorer offspring
cognitive function [13]. In fact, a recently published study has shown higher apoptosis
level in brain cells of mice offspring fed with a deficient FA diet [39], which could also
affect offspring cognitive function.
On the other hand, we found a negative effect of the periconceptional FAs use of
≥1000 µg/day on children’s attentional function at 4–5 years of age. In a similar way,
negative effects on other domains of neurodevelopment have been reported in previous
studies of the INMA project. Thus, an association between high periconceptional doses
of FAs and negative effects on the development of offspring [15,16] has been reported,
especially with negative effects on the cognitive development at age of 4–5 years [16].
These results have also been confirmed in animal studies. A growing number of animal
researches have displayed that high doses of FAs has been associated with the presence
of plasma unmetabolized FA producing alterations in the methylation pattern of several
key developmental genes in offspring [48] and alterations in the expression of genes in the
frontal cortex of offspring pups [49]. Considering that the frontal cortex is one of the most
important parts of the brain related to attentional function, we could contemplate this as an
explanation of the negative influence of high doses of FAs during periconceptional period
on attentional function of children at 4–5 years of age. All of this evidence, including our
results, offer safety concerns on the potential harmful effects of the use of high doses of
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FAs throughout the whole life as described by Selhub and Rosenberg [50], particularly for
children’s cognitive function.
Moreover, we found sex differences in some attentional function outcomes. Boys
of mothers using periconceptional FAs of <400 µg/day had increased omission errors
and HRT, and boys of mothers using periconceptional FAs of ≥1000 µg/day had an
increased speed response consistency throughout the test [HRT(SE)] and HRT compared
to mothers using periconceptional recommended FAs doses. The associations found in
girls are also negatives, but none reached statistical significance. Similarly, a recent study
of INMA Project found sex differences on neuropsychological development at 4–5 years
of age, being boys more vulnerable to prenatal pollutants exposure [51]. These results
may indicate that boys are more vulnerable to a deficient periconceptional FAs use than
girls. We did not find other studies that explore the effects of FAs use during pregnancy
on neuropsychological development depending on the children’s gender. However, a
similar result in the KCP-T test was found in children participating in the Health Outcomes
and Measures of the Environment (HOME) Study [52] in which omission errors were
associated with executive difficulties only in boys at 5 years of age. Brain model system
studies using image technologies could help us to understand the neurological basis of
this sex difference in attentional function outcomes. A recent study analyzed sex and age-
related brain changes in children and showed several differences between boys’ and girls’
brain development, including a higher connectivity in brain areas related to attentional
function, namely superior and left orbitofrontal cortex, in boys compared to girls [53].
Furthermore, animal studies can partly explain these differences by the fact that sexual
distinctions in brain neurodevelopment emerge during gestation, including the functional
connectivity of the prefrontal cortex. During gestation, girls demonstrated a longer range
of changes in functional connectivity in prefrontal cortex compared to boys; furthermore,
this connectivity decreased as gestational age increased more pronouncedly in boys [54].
Consequently, it is possible that boys need a greater contribution of FAs during earlier
stages of gestation than girls because it is the moment in which they present a greater
connectivity, and therefore are more sensitive to low or high periconceptional FAs doses.
Finally, we observed stronger associations in the Valencia area between K-CPT out-
comes (omission errors and HRT(SE)) in all children as well as in both boys and girls when
we performed pooled estimates. These differences could be in part explained by the fact
that children from Valencia were older than the children of the other areas of study at the
K-CPT examination. In this sense, studies using magnetic resonance imaging (MRI) technol-
ogy have described the functional connections in the whole brains of healthy children and
found that numerous global network parameters showed significant increases with age [53]
and a progressive functional maturation of attention brain allocation in adolescents [55].
This study has several limitations. We adjusted for a wide range of potential risk
factors, although we cannot discard potential residual confounding due to not including
potential confounding variables in the analyses, or bias due to subjects lost to follow up.
However, mothers of children who performed the K-CPT assessment, presented practically
equal age, educational, and socioeconomic statuses and FAs use, compared to those mothers
who were excluded due to unavailability of data for K-CPT test. Moreover, estimates from
self-reported supplementation may cause some misclassification, but any inaccuracy in
reporting should be non-differential. In this sense, to classify women according to their
FAs use, we used a FFQ which may be limited in estimating exact absolute values of
folate intake, but it showed an acceptable reproducibility for folate intake (r = 0.48) and
biochemical validity (r = 0.53) [30]. Finally, our results do not provide a possible explanation
of the mechanisms by which the use of non-recommended doses of FAs during pregnancy
could produce attentional dysfunction at 4–5 years of age. However, they can constitute an
argument to future research in this field.
The major strengths of this study include a large sample size and a prospective design
that minimized recall and selection bias. Additionally, we used a validated FFQ test to
estimate FAs intake and a standardized and computerized battery for K-CPT to evaluate
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attentional function, which may detect small changes on responses in children and provide
objective assessment. Although not specifically validated, these tests were administrated
by trainer interviewers which provided more unbiased assessment. Furthermore, the
results from sensitivity analysis reinforced the consistency of these findings. Finally, the
multicenter structure of the INMA Project showing different patterns of FAs use and the
detailed information on the doses of FAs used at each period of pregnancy, including a
crucial period of pregnancy, namely periconceptional period, may add value to our results.
5. Conclusions
In conclusion, this prospective mother–child cohort study shows that the periconcep-
tional non-recommended FAs doses (<400 µg/day or ≥1000 µg/day) compared to the FAs
use of 400–999 µg/day may have negative effects on attentional function development in
children at 4–5 years of age. Furthermore, the use of non-recommended FAs doses could
have different effects in girls and boys. Our findings add to existent evidence supporting a
potential adverse effect of the use of non-recommended FAs doses, so we suggest not using
these doses, unless medically prescribed. Nevertheless, additional studies are needed
to confirm the associations found between non-recommended FAs doses and attentional
function in children.
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